Zai Lab (ZLAB) said Monday it has dosed the first participant in a phase 1/1b trial evaluating the safety, tolerability, pharmacokinetics, and efficacy of its experimental therapy, ZL-1503, for atopic dermatitis.
The company said preclinical data showed ZL-1503 can simultaneously suppress inflammatory and itch-related pathways involved in the disease.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments